3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
15
NIH
5
NETWORK
2
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
pembrolizumab
135
Carboplatin
111
Paclitaxel
68
Cisplatin
65
Gemcitabine
62
Pemetrexed
59
Bevacizumab
50
Docetaxel
47
Fluorouracil
42
Oxaliplatin
40
Leucovorin
35
Dexamethasone
35
130-nm albumin-bound paclitaxel
34
durvalumab
32
atezolizumab
32
Cetuximab
32
Nivolumab
31
Capecitabine
28
Rituximab
27
Cyclophosphamide
27
Prednisone
26
Fulvestrant
25
enzalutamide
23
Lenalidomide
23
Letrozole
22
venetoclax
21
Irinotecan
21
Doxorubicin
19
ribociclib
16
pomalidomide
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Surgical Procedures, Operative
×
30 days
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled